# Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Canonical URL: https://biopharmsignal.com/news/ASMB/assembly-biosciences-announces-the-closing-of-its-offering-of-common-stock-and-pre-funded-warrants-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares
Ticker: ASMB
Company: Assembly Biosciences
Source: Assembly Biosciences
Published: 2026-06-25 13:46 EST
Original Source URL: https://investor.assemblybio.com
## Summary

SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced the closing of its previously announced underwritten registered offering of

## Article Body
SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced the closing of its previously announced underwritten registered offering of
## Recent Company News
- 2026-06-25 13:46 EST — [Assembly Biosciences Announces Upcoming Investor Conference Presentations](https://biopharmsignal.com/news/ASMB/assembly-biosciences-announces-upcoming-investor-conference-presentations) — Source: Assembly Biosciences
- 2026-06-25 13:46 EST — [Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares](https://biopharmsignal.com/news/ASMB/assembly-biosciences-announces-the-closing-of-its-offering-of-common-stock-and-pre-funded-warrants-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares) — Source: Assembly Biosciences
- 2026-06-25 13:46 EST — [Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases](https://biopharmsignal.com/news/ASMB/assembly-biosciences-announces-expansion-of-abi-6250-clinical-development-into-cholestatic-liver-diseases) — Source: Assembly Biosciences
- 2026-06-25 13:46 EST — [Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants](https://biopharmsignal.com/news/ASMB/assembly-biosciences-announces-pricing-of-100-million-offering-of-common-stock-and-pre-funded-warrants) — Source: Assembly Biosciences
- 2026-06-25 13:46 EST — [Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026](https://biopharmsignal.com/news/ASMB/assembly-biosciences-to-present-topline-phase-1a-data-on-hepatitis-delta-virus-entry-inhibitor-abi-6250-at-the-easl-congress-2026) — Source: Assembly Biosciences
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)